

Special Issue

Regulators of Metastasis-Related Signalling Targets in Cancer Cells

Message from the Guest Editors

This Special Issue, "Regulators of Metastasis related Signalling Targets in Cancer Cells," will focus on cancer cell metastasis regulation and molecular targets for preventing tumor metastasis. Metastasis causes more than 90% of cancer deaths. However, approved drugs or therapies specifically targeting metastasis have yet to be developed since metastasis is a highly complex, multistep process. During metastasis, primary tumor cells intravasate into, and disseminate within, the bloodstream and/or lymphatics, temporarily survive within the new inhospitable environment, and extravasate into secondary locations with mitogenic signals for regrowth. Tumor cells undergoing metastasis aberrantly regulate intracellular signaling molecules, cytoskeleton components, cell-cell interactions, and release of extracellular enzymes or signaling molecules. While multiple mechanisms responsible for promoting metastasis continue to be elucidated, there are still many unanswered questions regarding effective targets for metastatic inhibition. We would like to invite authors to submit research and review articles that focus on metastasis biology and potential therapeutics to prevent it.

Guest Editors

Dr. Michele I. Vitolo

Department of Pharmacology, Greenebaum National Cancer Institute Comprehensive Cancer Center, University of Maryland School of Medicine, 655 West Baltimore St., Bressler Research Bldg., Rm. 10-039, Baltimore, MD 21201, USA

Prof. Dr. Antonino Passaniti

Greenebaum National Cancer Institute Comprehensive Cancer Center, Department of Pathology, University of Maryland School of Medicine, 655 West Baltimore St., Bressler Research Bldg., Rm. 9-045, Baltimore, MD 21201, USA

Dr. Paul T. Wilder

Independent Contractor, FDA, Silver Spring, MD, USA

Deadline for manuscript submissions

closed (28 February 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/77746

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).